Your dog was diagnosed with Multicentric B-Cell Lymphoma. Most common haematopoietic neoplasm in dogs, representing ~24% of all canine neoplasms. Estimated incidence 20-107 per 100,000 dogs per year. B-cell phenotype accounts for 60-80% of cases. Compare 7 treatment options for dogs including CHOP Protocol (UW-Madison 25-week), COP Protocol, Single-Agent Doxorubicin — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Multicentric B-Cell Lymphoma
Canine Oncology Treatment Guide
Multicentric B-Cell Lymphoma
WHO Stage III-V
Round Cell
About This Cancer
Lymphoma is a cancer of white blood cells called lymphocytes, which are a key part of the immune system. In multicentric B-cell lymphoma, the malignant cells are B-lymphocytes — the type normally responsible for producing antibodies. The disease typically causes rapid, painless enlargement of lymph nodes throughout the body, which is why it is called 'multicentric.' It is the most common blood-cell cancer in dogs and one of the most frequently diagnosed canine cancers overall. Without treatment, the disease progresses quickly, with a typical survival of just four to six weeks. With chemotherapy, however, most dogs achieve remission, and the B-cell subtype generally responds better to treatment and carries a more favourable prognosis than T-cell lymphoma. Certain breeds, including Golden Retrievers, Boxers, and Bernese Mountain Dogs, are more frequently affected.
WHO Clinical Staging for Canine Lymphoma
Five-stage system based on extent of lymph node and organ involvement, with substage a (asymptomatic) or b (symptomatic).
Prognostic Factors(5)
Minimum Workup(10 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.